📊 PCVX Key Takeaways
Is Vaxcyte, Inc. (PCVX) a Good Investment?
Vaxcyte is a pre-commercial biopharmaceutical company facing an imminent liquidity crisis with only ~3 months of cash runway at current burn rates ($655.6M operating cash outflow annually vs $174M cash on hand). Accelerating losses (EPS deteriorated 48.2% YoY) and zero revenue indicate the company requires immediate capital infusion or major clinical/commercialization success to avoid insolvency.
Why Buy Vaxcyte, Inc. Stock? PCVX Key Strengths
- Strong balance sheet structure with minimal leverage (0.00x debt-to-equity ratio)
- Substantial asset base of $3.0B and positive stockholders equity of $2.7B
- Excellent liquidity position with 7.91x current and quick ratios
PCVX Stock Risks: Vaxcyte, Inc. Investment Risks
- Critical cash depletion: only 3 months of operational runway remaining at current burn rate
- Accelerating losses with EPS declining 48.2% YoY; pre-revenue stage with no commercialization visibility
- Inevitable capital raise required, creating significant dilution risk for existing shareholders
Key Metrics to Watch
- Cash runway and timing of next capital raise
- Clinical trial progress and regulatory approval milestones for pipeline products
- Monthly cash burn trends and any reduction in operating expenses
Vaxcyte, Inc. (PCVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.91x current ratio provides a solid financial cushion.
PCVX Profit Margin, ROE & Profitability Analysis
PCVX vs Healthcare Sector: How Vaxcyte, Inc. Compares
How Vaxcyte, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vaxcyte, Inc. Stock Overvalued? PCVX Valuation Analysis 2026
Based on fundamental analysis, Vaxcyte, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vaxcyte, Inc. Balance Sheet: PCVX Debt, Cash & Liquidity
PCVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vaxcyte, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-4.14 indicates the company is currently unprofitable.
PCVX Revenue Growth, EPS Growth & YoY Performance
Vaxcyte, Inc. Dividends, Buybacks & Capital Allocation
PCVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vaxcyte, Inc. (CIK: 0001649094)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 8, 2026 | 4 | xslF345X06/wk-form4_1775680362.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/wk-form4_1775246763.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773875008.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/wk-form4_1773264320.xml | View → |
| Mar 11, 2026 | 4 | xslF345X05/wk-form4_1773264290.xml | View → |
❓ Frequently Asked Questions about PCVX
What is the AI rating for PCVX?
Vaxcyte, Inc. (PCVX) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCVX's key strengths?
Claude: Strong balance sheet structure with minimal leverage (0.00x debt-to-equity ratio). Substantial asset base of $3.0B and positive stockholders equity of $2.7B.
What are the risks of investing in PCVX?
Claude: Critical cash depletion: only 3 months of operational runway remaining at current burn rate. Accelerating losses with EPS declining 48.2% YoY; pre-revenue stage with no commercialization visibility.
What is PCVX's revenue and growth?
Vaxcyte, Inc. reported revenue of N/A.
Does PCVX pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
Where can I find PCVX SEC filings?
Official SEC filings for Vaxcyte, Inc. (CIK: 0001649094) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCVX's EPS?
Vaxcyte, Inc. has a diluted EPS of $-5.63.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PCVX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vaxcyte, Inc. has a STRONG SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PCVX stock overvalued or undervalued?
Valuation metrics for PCVX: ROE of -28.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PCVX stock in 2026?
Our dual AI analysis gives Vaxcyte, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCVX's free cash flow?
Vaxcyte, Inc.'s operating cash flow is $-655.6M, with capital expenditures of $13.7M.
How does PCVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -28.5% (avg: 15%), current ratio 7.91 (avg: 2).